Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery (DACAB)

Compare the Efficacy of Different Antiplatelet Therapy Strategy After Coronary Artery Bypass Graft Surgery

The study population will include all patients undergoing elective CABG. Consent and randomization will occur before surgery. Total 500 patients undergoing elective CABG will be randomly assigned into three groups with 1:1:1 ratio(167 patients per group) in this open-label study. All the enrolled patients will stop oral antiplatelet drugs according to local protocol before the surgery. Within the first 24 hours after surgery, study medication should be restarted and continued for 12 months. Arm A will restart oral antiplatelet drugs by giving aspirin 100mg qd, Arm B will also restart oral antiplatelet drugs by giving ticagrelor 90mg bid plus aspirin 100mg qd and Arm C will also restart oral antiplatelet drugs by giving ticagrelor 90mg bid. Treatment will continue for 12 months, at which time patients will undergo a multislice computed tomography angiography to assess vein graft patency.

This study is designed to show the superiority of ticagrelor and ticagrelor plus aspirin as compared with aspirin monotherapy respectively for the 1-year primary efficacy end point of vein graft patency.

Study Overview

• Status: Completed
• Conditions: Coronary Artery Bypass; Antiplatelet Agents
• Intervention / Treatment: Drug: Ticagrelor; Drug: Aspirin

Detailed Description

The study is designed to show the superiority of ticagrelor and ticagrelor plus aspirin as compared with aspirin monotherapy respectively for the 1-year primary efficacy end point of vein graft patency. The primary comparison includes two separate parts. One is to demonstrate T+A better than A and the other is T better than A.

One year rate of vein graft patency in the aspirin group is estimated as 80%. The assumed rate of ticagrelor plus aspirin is 90%. With a two-sided alpha level 0.05 and 80% power, 199 grafts to each group are required. On the other hand, if we assume the rate of ticagrelor monotherapy has the 1-year vein graft patency rate of 87%, under the same two-sided 0.05 alpha 441 grafts in each arm will offer 80% power to show the superiority of ticagrelor along for the primary efficacy end point.

Combined the above two assumptions, if the allocation rate is 1:1:1, this study needs to recruit 1,323 grafts in total (441 in each) to achieve the pre-specified power for both the two comparisons (T+A vs. A and T vs. A).

The principle investigator assumes that the average number of the vien grafts in one patient is 2.7-3.0. With this assumption, 500 patients are to be recruited, which will provide us a total of 1350 - 1500 grafts.

According to the above, this study will be a confirmatory clinical trial to the primary endpoint.

• Study Type: Interventional
• Enrollment (Actual): 500
• Phase: Phase 4

Contacts and Locations

Study Locations

• China
  • Henan
    • Zhengzhou, Henan, China
      • Henan Provincial People's Hospital
  • Jiangsu
    • Nanjing, Jiangsu, China
      • Jiangsu Province Hospital
    • Nanjing, Jiangsu, China
      • Nan Jing First Hospital
  • Shanghai
    • Shanghai, Shanghai, China, 200433
      • Changhai Hospital of Shanghai
    • Shanghai, Shanghai, China, 200025
      • Ruijin Hospital, Shanghai Jiaotong University School Of Medicine
    • Shanghai, Shanghai, China, 200092
      • Xinhua Hospital, Shanghai Jiaotong University School of Medicine

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years to 80 years (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Patients able to provide written informed consent
• Provision of informed consent prior to any study specific procedures
• Female and male patients aged 18-80 years
• Indication for CABG surgery

Exclusion Criteria:

• Cardiogenic shock, haemodynamic instability
• Need for urgent revascularization within 5 days from presentation
• Single vessel disease
• Two vessel disease with normal left ventricular function (> 50%)
• Need for concomitant other cardiac surgery (e.g. valve replacement)
• Need for dual antiplatelet treatment for the patients undergoing CABG after acute coronary syndrome(ACS)
• Contraindication for aspirin and ticagrelor use(e.g. known allergy)
• History of bleeding diathesis within 3 months prior presentation
• History of significant GI bleed within 1 year prior presentation
• History of peptic ulcer without GI bleeding in past 3 years
• History of intracranial hemorrhage
• History of moderate to severe liver impairment
• Patient requires dialysis
• Patient with an increased risk of bradycardic events (as patients without a pacemaker who have sick sinus syndrome, 2nd or 3rd degree arteriolar-venular block or bradycardic-related syncope)
• Need vitamin K antagonist therapy after bypass surgery eg. persistent atrial fibrillation, mechanical valves
• Known, clinically important thrombocytopenia(i.e. < 100*109/L)
• Known, clinically important anaemia (i.e. <100g/L)
• Participation in another investigational drug or device study in the last 30 days
• Pregnancy or lactation(for premenopausal women 2 methods of reliable contraception, one of which must barrier method, are required)
• Concomitant oral or intravenous therapy with strong cytochrome P450 3A4(CYP3A4) inhibitors, CYP3A4 substrates with narrow therapeutic indices, or strong CYP3A4 inducers which cannot be stopped for the course of the study (strong inhibitors: ketoconazole, itraconazole, voriconazole, telithromycin, clarithromycin, nefazadone, ritonavir, saquinavir, nelfinavir, indinavir, atazanavir, over 1 litre daily of grapefruit juice. Substrates with narrow therapeutic index: cyclosporine, quinidine. Strong inducers: rifampin, phenytoin, carbamazepine. )
• Any other condition such as active cancer
• Life expectancy less than 12 months that may result in protocol non-compliance or a risk for being lost to follow up
• Indication for major surgery(e.g. cancer treatment, carotid surgery, cerebral surgery, major vascular surgery)

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Parallel Assignment
• Masking: None (Open Label)

Number of Arms

3

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: Aspirin; aspirin 100mg tablet by mouth daily for 12 months	Drug: Aspirin
Experimental: Ticagrelor plus Aspirin; ticagrelor 90mg tablet by mouth twice daily and aspirin 100mg tablet by mouth daily for 12 months	Drug: Ticagrelor; Drug: Aspirin
Experimental: Ticagrelor; ticagrelor 90mg tablet by mouth twice daily for 12 months	Drug: Ticagrelor

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Patency of Saphenous Vein Grafts	assessed by multislice computed tomography angiography (MSCTA) or coronary angiography(CAG). FitzGibbon grade A (stenosis <50%) is defined as "patency".	up to 12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Patency of Saphenous Vein Grafts	assessed by MSCTA or CAG. FitzGibbon grade A (stenosis <50%) is defined as "patency".	up to 7 days
The Rate of Post-operative Atrial Fibrillation After CABG.	Number of Participants with Post-operative Atrial Fibrillation after CABG	up to 7 days
The Rate of Freedom From Angina According to Canadian Cardiovascular Society (CCS) Classification	Number of Participants Free of Angina per CCS Classification	up to 12 months
The Number of Major Adverse Cardiovascular Event (MACE)	MACE, composite of CV death, myocardial infarction or stroke (ischaemic or unknown etiology)	up to 12 months
Number of the Major Bleeding Events	According to modified TIMI criteria, the "Major Bleeding Events" is defined as the combination of CABG-related bleeding and non-CABG-related major bleeding(Intracranial bleeding, Clinically overt signs of hemorrhage with hemoglobin drop ≥5 g/dL and Fatal bleeding).	up to 12 months

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
The Rate of Gastroduodenal Injury Assessed by Esophagogastroduodenoscopy (EGD)	Not all but the patients recruited in Ruijin Hospital	at 12 months

Collaborators and Investigators

• Sponsor: Ruijin Hospital
• Investigators: Principal Investigator: Qiang Zhao, MD.PhD, Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China; Study Director: Yunpeng Zhu, MD., Ruijin Hospital Shanghai Jiao Tong University School of Medicine, Shanghai, China

Publications and helpful links

General Publications

• Zhao Q, Zhu Y, Xu Z, Cheng Z, Mei J, Chen X, Wang X. Effect of Ticagrelor Plus Aspirin, Ticagrelor Alone, or Aspirin Alone on Saphenous Vein Graft Patency 1 Year After Coronary Artery Bypass Grafting: A Randomized Clinical Trial. JAMA. 2018 Apr 24;319(16):1677-1686. doi: 10.1001/jama.2018.3197.

Study record dates

Study Major Dates

• Study Start: July 1, 2014
• Primary Completion (Actual): January 1, 2017
• Study Completion (Actual): January 1, 2017

Study Registration Dates

• First Submitted: July 24, 2014
• First Submitted That Met QC Criteria: July 24, 2014
• First Posted (Estimate): July 28, 2014

Study Record Updates

• Last Update Posted (Actual): August 13, 2019
• Last Update Submitted That Met QC Criteria: August 4, 2019
• Last Verified: August 1, 2019

More Information

Terms related to this study

• Keywords: Ticagrelor; CABG; Antiplatelet
• Additional Relevant MeSH Terms: Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Peripheral Nervous System Agents; Enzyme Inhibitors; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Fibrinolytic Agents; Fibrin Modulating Agents; Platelet Aggregation Inhibitors; Cyclooxygenase Inhibitors; Antipyretics; Purinergic P2Y Receptor Antagonists; Purinergic P2 Receptor Antagonists; Purinergic Antagonists; Purinergic Agents; Aspirin; Ticagrelor
• Other Study ID Numbers: ISSBRIL0211

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No
• product manufactured in and exported from the U.S.: No